Generisk Daclatasvir - , Daklinza, Natdac, Hepcinat, Myhep, Sofovir

Generic Daklinza is an antiviral medicine that precludes hepatitis C virus (HCV) to spread out in your body. It is used to cure genotype 3 chronic hepatitis C in mature patients without cirrhosis. This medicine is taken with another antiviral drug named sofosbuvir.

Natdac® is an inhibitor of the viral (hepatitis C virus) protein NS5A, which is used in the replication of hepatitis C virus within the liver cells (hepatocytes) and, thus, prevents the virus from entering infected hepatocytes into the blood. Thanks to this action, it is possible to prevent the spread of the virus in the body. Natdac® (daсlatasvir) is a highly specific direct action agent against hepatitis C virus (HCV) and has no pronounced activity against other RNA and DNA containing viruses, including human immunodeficiency virus (HIV). Natdac®, as an inhibitor of the nonstructural protein 5A (NS5A), a multifunctional protein required for HCV replication, suppresses two stages of the life cycle of the virus-viral RNA replication and virion assembly.

Hepcinat® - innehåller 400 mg Sofosbuvir, den senaste drogen som utvecklats av det Indiska företaget Natco Pharma med hjälp av högteknologisk utrustning, med alla nödvändiga standarder och krav. Läkemedlet används för att behandla kronisk hepatit C. Behandling med sofosbuvir används i ett komplex med andra antivirala läkemedel under "behandling utan interferon" i nästan alla ledande kliniker runt om i världen, eftersom detta läkemedel, som har genomgått en hel del kliniska och laborativa studier, visade goda resultat. Effekten av detta nya läkemedel för olika genotyper av virus är 92-96%.

Myhep® - sofosbuvir 400mg - is used to treat chronic hepatitis C as a component of a combined antiviral therapy regimen in adult patients in combination with other medications. Myhep® is a direct-acting antiviral that inhibits the RNA-dependent NS5B polymerase of the hepatitis C virus, which is essential for viral replication. Myhep® is a drug manufactured by Mylan Pharmaceuticals, based in India. All the products of this company are produced on modern equipment of a large plant built according to all norms and regulations of the World Health Organization.

Sofovir® is an Indian registered licensed analog of Sovaldi (Sofosbuvir). It is an inhibitor of the NS5B polymerase of hepatitis C virus (HCV) that contains 400mg of the active substance Sofosbuvir. It is used to treat chronic hepatitis C as a component of a combined antiviral therapy regimen in adults. Sofovir® can be used by patients who have not been treated before or who have had unsuccessful experience in the treatment of hepatitis C. Good efficacy has been shown with concomitant serious liver pathologies like cirrhosis and HIV infection.